These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 9862706)
1. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. Wahlsten JL; Mills CD; Ramakrishnan S J Immunol; 1998 Dec; 161(12):6761-7. PubMed ID: 9862706 [TBL] [Abstract][Full Text] [Related]
2. Separation of function between the domains of toxic shock syndrome toxin-1. Wahlsten JL; Ramakrishnan S J Immunol; 1998 Jan; 160(2):854-9. PubMed ID: 9551921 [TBL] [Abstract][Full Text] [Related]
4. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598 [TBL] [Abstract][Full Text] [Related]
5. Dissection of the function of HLA class II and costimulation in B cell-mediated and toxic shock syndrome toxin-1-induced T cell proliferation. Dennig D; O'Reilly RJ J Immunol; 1993 Jun; 150(12):5231-40. PubMed ID: 7685791 [TBL] [Abstract][Full Text] [Related]
6. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131 [TBL] [Abstract][Full Text] [Related]
7. The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1. Karp DR; Teletski CL; Scholl P; Geha R; Long EO Nature; 1990 Aug; 346(6283):474-6. PubMed ID: 2377209 [TBL] [Abstract][Full Text] [Related]
8. Activation of murine T cells by toxic shock syndrome toxin-1. The toxin-binding structures expressed on murine accessory cells are MHC class II molecules. Uchiyama T; Tadakuma T; Imanishi K; Araake M; Saito S; Yan XJ; Fujikawa H; Igarashi H; Yamaura N J Immunol; 1989 Nov; 143(10):3175-82. PubMed ID: 2509554 [TBL] [Abstract][Full Text] [Related]
9. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. Tiedemann RE; Fraser JD J Immunol; 1996 Nov; 157(9):3958-66. PubMed ID: 8892628 [TBL] [Abstract][Full Text] [Related]
10. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Arad G; Levy R; Hillman D; Kaempfer R Nat Med; 2000 Apr; 6(4):414-21. PubMed ID: 10742148 [TBL] [Abstract][Full Text] [Related]
11. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules. Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498 [TBL] [Abstract][Full Text] [Related]
12. Staphylococcal cell membrane antigen, a possible antigen in post-methicillin resistant Staphylococcus aureus (MRSA) infection nephritis and IgA nephropathy, exhibits high immunogenic activity that is enhanced by superantigen. Shimizu Y; Sakurai H; Hirayama K; Seki M; Yoh K; Yamagata K; Koyama A J Nephrol; 2005; 18(3):249-56. PubMed ID: 16013011 [TBL] [Abstract][Full Text] [Related]
13. Carboxy-terminal residues of major histocompatibility complex class II-associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells. Wen R; Broussard DR; Surman S; Hogg TL; Blackman MA; Woodland DL Eur J Immunol; 1997 Mar; 27(3):772-81. PubMed ID: 9079821 [TBL] [Abstract][Full Text] [Related]
14. Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin. A dual-anchored tumor cell vaccine and its antitumor effect. Yi P; Yu H; Ma W; Wang Q; Minev BR Cancer; 2005 Apr; 103(7):1519-28. PubMed ID: 15739200 [TBL] [Abstract][Full Text] [Related]
15. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Acharya KR; Passalacqua EF; Jones EY; Harlos K; Stuart DI; Brehm RD; Tranter HS Nature; 1994 Jan; 367(6458):94-7. PubMed ID: 8107781 [TBL] [Abstract][Full Text] [Related]
16. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen. Hess AD; Thoburn C; Chen W; Miura Y; Van der Wall E Clin Immunol; 2001 Oct; 101(1):67-76. PubMed ID: 11580228 [TBL] [Abstract][Full Text] [Related]
17. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury. Brogan PA; Shah V; Klein N; Dillon MJ Arthritis Rheum; 2004 Feb; 50(2):589-97. PubMed ID: 14872503 [TBL] [Abstract][Full Text] [Related]
18. Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection. Cui JC; Hu DL; Lin YC; Qian AD; Nakane A FEMS Immunol Med Microbiol; 2005 Jul; 45(1):45-51. PubMed ID: 15985222 [TBL] [Abstract][Full Text] [Related]
19. Activation of T cells by superantigen in class II-negative mice. Avery AC; Markowitz JS; Grusby MJ; Glimcher LH; Cantor H J Immunol; 1994 Dec; 153(11):4853-61. PubMed ID: 7963549 [TBL] [Abstract][Full Text] [Related]
20. Engagement of MHC-class II molecules by staphylococcal exotoxins delivers a comitogenic signal to human B cells. Fuleihan R; Mourad W; Geha RS; Chatila T J Immunol; 1991 Mar; 146(5):1661-6. PubMed ID: 1847171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]